Citations

Mayo Clinic

Clear

1459 citation(s) found for "Wu, Sean M".

NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
Wen, Ti , Barham, Whitney , Li, Ying , Zhang, Henan , Gicobi, Joanina K. , Hirdler, Jacob B. , Liu, Xin , Ham, Hyoungjun , Martinez, Kodi E. Peterson, Lavoie, Roxane R. , Monie, Dileep D. , An, Zesheng , Harrington, Susan M. , Wu, Xiaosheng , Guo, Ruifeng , Dronca, Roxana , Yan, Yiyi , Liu, Minetta C. , Vasmatzis, George , Billadeau, Daniel D. , Peterson Martinez, Kodi E, Correia, Cristina , Monie, Dileep D , Dronca, Roxana S., Mansfield, Aaron S , Yan, Yiyi , Markovic, Svetomir , Park, Sean S , Liu, Minetta , Billadeau, Daniel D , Dong, Haidong , Guo, Ruifeng , Martinez, Kodi, Lucien, Fabrice , Li, Hu , Correia, Cristina , Mansfield, Aaron S. , Markovic, Svetomir N. , Park, Sean S. , Sun, Jie , Qin, Hong , Dong, Haidong

Cancer Immunology Research | December 15, 2021 | Volume: 10 | Issue: 2 | Pages: 162-181

10.1158/2326-6066.cir-21-0539 | PMID 34911739 Get It

Abstract Cytotoxic CD8+ T cells (CTL) are a crucial component of the immune system notable for their ability to eliminate rapidly proliferating malignant cells. However, the T-cell intrinsic factors required for human CTLs to accomplish highly efficient antitumor cytotoxicity are not well defined. By evaluating human CD8+ T cells from responders versus nonresponders to treatment with immune checkpoint inhibitors, we sought to identify key factors associated with effective CTL function. Single-cell RNA-sequencing analysis of peripheral CD8+ T cells from patients treated with anti–PD-1 therapy showed that cells from nonresponders exhibited decreased expression of the cytolytic granule-associated molecule natural killer cell granule protein-7 (NKG7). Functional assays revealed that reduced NKG7 expression altered cytolytic granule number, trafficking, and calcium release, resulting in decreased CD8+ T-cell–mediated killing of tumor cells. Transfection of T cells with NKG7 mRNA was sufficient to improve the tumor-cell killing ability of human T cells isolated from nonresponders and increase their response to anti–PD-1 or anti–PD-L1 therapy in vitro. NKG7 mRNA therapy also improved the antitumor activity of murine tumor antigen–specific CD8+ T cells in an in vivo model of adoptive cell therapy. Finally, we showed that the transcription factor ETS1 played a role in regulating NKG7 expression. Together, our results identify NKG7 as a necessary component for the cytotoxic function of CD8+ T cells and establish NKG7 as a T-cell–intrinsic therapeutic target for enhancing cancer immunotherapy. See related article by Li et al., p. 154.
Investigating the Immunopathogenic Mechanisms Underlying MOGAD
McCombe, Jennifer A. , Chen, John J. , Ζεκερίδου, Αναστασία , Lucchinetti, Claudia F. , Pittock, Sean J. , Zekeridou, Anastasia , Pittock, S J , Chen, John J , Flanagan, Eoin P.

Annals of Neurology | December 4, 2021 | Volume: 91 | Issue: 2 | Pages: 299-300

10.1002/ana.26279 | PMID 34862992 Get It

National Comprehensive Cancer Network investigational drug service consensus recommendations
Amin, Sapna, Polley, Stephen , DeFrates, Sean, Finnes, Heidi D. , Kinsman, Katharine, MacDonald, Elyse A. , Dean, Latanya, DeWitt, Lorri L., Harvey, Caroline , Leung, Tzewah Vivian, Moll, Emily A, O’Neill, Gerald P. , Redic, Kimberly, Park, Sharon F, Harvey, Caroline, Johnston, Susan S.

American Journal of Health-System Pharmacy | December 1, 2021 | Volume: 79 | Issue: 6 | Pages: 486-491

10.1093/ajhp/zxab455 | PMID 34849539 Get It

Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series
D’Andre, Stacy D. , McAllister, Sean D. , Nagi, Jasdeepa, Ruiz-Macias, Eduardo, Loprinzi, Charles L. , D'Andre, Stacy , Giridhar, Karthik V.

Integrative Cancer Therapies | November 29, 2021 | Volume: 20 | Issue: No issue available | Pages: No page available

10.1177/15347354211061739 | PMID 34841942 Get It

Background Chemotherapy-induced peripheral neuropathy is a common and often severe side effect from many chemotherapeutic agents, with limited treatment options. There is no literature on the use of topical cannabinoids for chemotherapy-induced neuropathy. Case Presentations The current manuscript presents a case series of patients presenting in oncology clinics at Sutter Health, CA and Mayo Clinic, Rochester, MN from April 2019 to December 2020 with chemotherapy-induced peripheral neuropathy who used topical creams containing the cannabinoids delta-nine-tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Conclusions This case series suggests that topical cannabinoids may be helpful for patients with chemotherapy-induced peripheral neuropathy. This paper also discusses the potential mechanisms of action by which topical cannabinoids might alleviate established CIPN symptoms. A randomized placebo-controlled trial using a standardized product is planned to study the actual efficacy of such treatment.
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
Redenbaugh, Vyanka , Montalvo, Mayra , Sechi, Elia , Fryer, James P., Lennon, Vanda A. , Mills, John R. , Wingerchuk, Dean M. , Chen, John J. , Bhatti, M. Tariq , López‐Chiriboga, A. Sebastian , Pittock, Sean J, Pittock, Sean J. , Lopez-Chiriboga, A Sebastian , Pittock, Sean J , Flanagan, E P , Pittock, S J , Chen, John J , Sechi, Elia , Redenbaugh, Vyanka , Buciuc, Marina , McKeon, Andrew , Weinshenker, Brian G. , Flanagan, Eoin P.

Multiple Sclerosis Journal - Experimental, Translational and Clinical | November 26, 2021 | Volume: 7 | Issue: 4 | Pages: No page available

10.1177/20552173211052656 | PMID 34868626 Get It

Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.
Avoiding Retained Surgical Items at an Academic Medical Center: Sustainability of a Surgical Quality Improvement Project
Bearden, Brenda A, Kollengode, Anantha, Nienow, Joseph M., Weisbrod, Cheryl A., Dowdy, Sean C. , Amstutz, Gwendolyn J., Narr, Bradly J., Cima, Robert R. , Bearden, Brenda A

American Journal of Medical Quality | November 22, 2021 | Volume: 37 | Issue: 3 | Pages: 236-245

10.1097/jmq.0000000000000030 | PMID 34803134 Get It

Unintentionally retained surgical items (RSIs) are a serious complication representing a surgical “Never” event. The authors previously reported the process and significant improvement over a 3-year multiphased quality improvement RSI reduction effort that included sponge-counting technology. Herein, they report the sustainability of that effort over the decade following the formal quality improvement project conclusion. This retrospective analysis includes descriptive and qualitative data collected during RSI event root cause analysis. Between January 2009 and December 2019, 640 889 operations were performed with 24 RSIs reported. The resulting RSI rate of 1 per 26 704 operations represent a 486% performance improvement compared to the preintervention rate of 1 per 5500 operations. The interval, in days, between RSI events increased to 160 from 26 during the preintervention phase. Cotton sponges were the most retained RSI despite the use of sponge-counting technology. A significant and sustained reduction in RSI is possible after designing a sustainable comprehensive multidisciplinary effort.
RADT-10. DEVELOPMENT AND INTERNAL VALIDATION OF A PREDICTIVE SCORE FOR VERTEBRAL COMPRESSION FRACTURE AFTER STEREOTACTIC BODY RADIATION THERAPY FOR SPINAL METASTASES
Johnson‐Tesch, Benjamin A., Marion, Joseph , Mullikin, Trey C. , Harmsen, William S. , Rose, Peter S. , Kim, Dong Kun , Costello, Brian A. , Morris, Jonathan, Gao, Robert W. , Lucido, J. John , Olivier, Kenneth R. , Owen, Dawn , Stish, Bradley J. , Waddle, Mark R. , Brown, Paul D. , Merrell, Kenneth W. , Kowalchuk, Roman O. , Siontis, Brittany L. , Shiraishi, Satomi , Trifiletti, Daniel M. , Laack, Nadia N. , Park, Sean S.

Neuro-Oncology | November 18, 2021 | Volume: 23 | Issue: Supplement_6 | Pages: vi43-vi43

10.1093/neuonc/noab196.168 Get It

Abstract PURPOSE Vertebral compression fracture (VCF) is a potential adverse effect following stereotactic body radiation therapy (SBRT) for spinal metastases. In this analysis, we developed and internally validated a risk stratification model for VCF. METHODS From an initial set of 680 treatments, we excluded those with proton therapy, prior surgical intervention, or missing data. The final dataset had 464 treatments in 313 patients. Delineations of VCF and all radiographic components of the spinal instability neoplastic score (SINS) were determined by a radiologist. Recursive partitioning analysis (RPA) was conducted using separate training (70%), internal validation (15%), and test (15%) sets. The log-rank test was used as the criterion for node splitting. RESULTS With a median follow-up of 21 months, we identified 84 VCF (18%), including 65 (77%) de novo and 19 (23%) progressive fractures. There was a median 9 months (IQR: 3 – 21) to VCF. From an initial set of 15 candidate variables, six were identified using the backwards selection method, feature importance testing, and a correlation heatmap. Four were then selected in the highest-fidelity RPA models: epidural tumor extension, lumbar location, gross tumor volume > 10 cc, and SINS > 6. One point was assigned to each variable, and the resulting multivariate Cox model had a concordance of 0.760. Each one point increase in score was associated with increasing rates of VCF. Low-risk lesions (score: 0-1, n=273) had 2-year freedom from VCF of 92%, compared to 80% for intermediate-risk (score: 2, n=99) and 56% (score: 3-4, n=92) for high-risk lesions (p < 0.0001). Cumulative incidence curves with death as a competing risk showed increased VCF with higher scores via Gray’s test (p < 0.001). CONCLUSIONS Our internally-validated model identifies a subgroup of patients with high risk for VCF who may benefit from prophylactic surgical stabilization or vertebroplasty.
Empowering Women as Leaders in Pediatric Anesthesiology: Methodology, Lessons, and Early Outcomes of a National Initiative
Schwartz, Jamie McElrath , Markowitz, Scott D. , Yanofsky, Samuel D., Tackett, Sean , Berenstain, Laura K. , Schwartz, Lawrence , Flick, Randall P., Heitmiller, Eugenie S., Fiadjoe, John E. , Lee, Helen H. , Honkanen, Anita , Malviya, Shobha , Cladis, Franklyn P. , Lee, Jennifer K. , Flick, Randall, Deutsch, Nina

Anesthesia & Analgesia | November 16, 2021 | Volume: 133 | Issue: 6 | Pages: 1497-1509

10.1213/ane.0000000000005740 | PMID 34517375 Get It

Research has shown that women have leadership ability equal to or better than that of their male counterparts, yet proportionally fewer women than men achieve leadership positions and promotion in medicine. The Women’s Empowerment and Leadership Initiative (WELI) was founded within the Society for Pediatric Anesthesia (SPA) in 2018 as a multidimensional program to help address the significant career development, leadership, and promotion gender gap between men and women in anesthesiology. Herein, we describe WELI’s development and implementation with an early assessment of effectiveness at 2 years. Members received an anonymous, voluntary survey by e-mail to assess whether they believed WELI was beneficial in several broad domains: career development, networking, project implementation and completion, goal setting, mentorship, well-being, and promotion and leadership. The response rate was 60.5% (92 of 152). The majority ranked several aspects of WELI to be very or extremely valuable, including the protégé-advisor dyads, workshops, nomination to join WELI, and virtual facilitated networking. For most members, WELI helped to improve optimism about their professional future. Most also reported that WELI somewhat or absolutely contributed to project improvement or completion, finding new collaborators, and obtaining invitations to be visiting speakers. Among those who applied for promotion or leadership positions, 51% found WELI to be somewhat or absolutely valuable to their application process, and 42% found the same in applying for leadership positions. Qualitative analysis of free-text survey responses identified 5 main themes: (1) feelings of empowerment and confidence, (2) acquisition of new skills in mentoring, coaching, career development, and project implementation, (3) clarification and focus on goal setting, (4) creating meaningful connections through networking, and (5) challenges from coronavirus disease 2019 (COVID-19) and the inability to sustain the advisor-protégé connection. We conclude that after 2 years, the WELI program has successfully supported career development for the majority of protégés and advisors. Continued assessment of whether WELI can meaningfully contribute to attainment of promotion and leadership positions will require study across a longer period. WELI could serve as a programmatic example to support women’s career development in other subspecialties.
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Ga‐PSMA‐11 PET Using Cyclotron‐Produced 68Ga
Thompson, Scott M. , Suman, Garima , Chen, Zongming E., Jondal, Danielle E. , Patra, Anurima , Ehman, Eric C. , Andrews, James C. , Fleming, Chad J. , Welch, Brian T. , Kurup, A. Nicholas , Roberts, Lewis R. , Watt, Kymberly D. , Truty, Mark J. , Smoot, Rory L. , Yin, Jun , Jacobson, Mark, Kemp, Bradley J. , Venkatesh, Sudhakar K. , Johnson, Geoffrey B. , Woodrum, David A. , Goenka, Ajit H. , Chen, Zong-ming E., Kurup, Anil N, Watt, K D , Cleary, Sean P. , Wang, Chen , Fogarty, Zachary C , Venkatesh, Sudhakar K , Roberts, Lewis R , Smoot, Rory L , Johnson, Geoffrey B , Kurup, Anil N , Thompson, Scott , Torbenson, Michael , Heimbach, Julie K. , Tran, Nguyen H. , Mahipal, Amit , Zemla, Tyler , Wang, Chen , Fogarty, Zachary C.

Hepatology Communications | November 16, 2021 | Volume: 6 | Issue: 5 | Pages: 1172-1185

10.1002/hep4.1861 | PMID 34783177 Get It

Prostate‐specific membrane antigen (PSMA) is a validated target for molecular diagnostics and targeted radionuclide therapy. Our purpose was to evaluate PSMA expression in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and hepatic adenoma (HCA); investigate the genetic pathways in HCC associated with PSMA expression; and evaluate HCC detection rate with 68Ga‐PSMA‐11 positron emission tomography (PET). In phase 1, PSMA immunohistochemistry (IHC) on HCC (n = 148), CCA (n = 111), and HCA (n = 78) was scored. In a subset (n = 30), messenger RNA (mRNA) data from the Cancer Genome Atlas HCC RNA sequencing were correlated with PSMA expression. In phase 2, 68Ga‐PSMA‐11 PET was prospectively performed in patients with treatment‐naïve HCC on a digital PET scanner using cyclotron‐produced 68Ga. Uptake was graded qualitatively and semi‐quantitatively using standard metrics. On IHC, PSMA expression was significantly higher in HCC compared with CCA and HCA (P < 0.0001); 91% of HCCs (n = 134) expressed PSMA, which principally localized to tumor‐associated neovasculature. Higher tumor grade was associated with PSMA expression (P = 0.012) but there was no association with tumor size (P = 0.14), fibrosis (P = 0.35), cirrhosis (P = 0.74), hepatitis B virus (P = 0.31), or hepatitis C virus (P = 0.15). Overall survival tended to be longer in patients without versus with PSMA expression (median overall survival: 4.2 vs. 1.9 years; P = 0.273). FGF14 (fibroblast growth factor 14) mRNA expression correlated positively (rho = 0.70; P = 1.70 × 10‐5) and MAD1L1 (Mitotic spindle assembly checkpoint protein MAD1) correlated negatively with PSMA expression (rho = −0.753; P = 1.58 × 10‐6). Of the 190 patients who met the eligibility criteria, 31 patients with 39 HCC lesions completed PET; 64% (n = 25) lesions had pronounced 68Ga‐PSMA‐11 standardized uptake value: SUVmax (median [range] 9.2 [4.9‐28.4]), SUVmean 4.7 (2.4‐12.7), and tumor‐to‐liver background ratio 2 (1.1‐11). Conclusion: Ex vivo expression of PSMA in neovasculature of HCC translates to marked tumor avidity on 68Ga‐PSMA‐11 PET, which suggests that PSMA has the potential as a theranostic target in patients with HCC.